Image For Activity Cover
PCSS MAT Half and Half Training 2021-2022
Introduction

This program will provide an array of background and clinical information concerning the pharmacological use of buprenorphine for the treatment of opioid use disorder. 

At the conclusion of this activity participants should be able to:

 

  • Screen and identify patients with OUD and define evidence-based treatments.
  • Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
  • Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
  • Explain the process of buprenorphine induction as well as stabilization and maintenance.
  • Discuss all FDA approved antagonist and agonist medications to treat OUD.
  • Discuss basic office protocols including medical record documentation and confidentiality.
  • Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
Target Audience
This activity will assist physicians, nurse practitioners, and physician assistants who wish to learn to prescribe buprenorphine for the treatment of opioid use disorders.
Method of participation in the activity
To be awarded a maximum of 4 CME/CE credits you must:

Review 3 training modules (4 hours) provided in this activity.
Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your certificate*.

*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
 
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.



Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email PCSS-MOUD.

ORN
opioidresponsenetwork.org

Powered By